Εμφάνιση απλής εγγραφής

dc.creatorPaciaroni M., Bandini F., Agnelli G., Tsivgoulis G., Yaghi S., Furie K.L., Tadi P., Becattini C., Zedde M., Abdul-Rahim A.H., Lees K.R., Alberti A., Venti M., Acciarresi M., D’Amore C., Mosconi M.G., Cimini L.A., Altavilla R., Volpi G., Bovi P., Carletti M., Rigatelli A., Cappellari M., Putaala J., Tomppo L., Tatlisumak T., Marcheselli S., Pezzini A., Poli L., Padovani A., Masotti L., Vannucchi V., Sohn S.-I., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Ntaios G., Athanasakis G., Makaritsis K., Karagkiozi E., Vadikolias K., Liantinioti C., Chondrogianni M., Mumoli N., Consoli D., Galati F., Sacco S., Carolei A., Tiseo C., Corea F., Ageno W., Bellesini M., Colombo G., Silvestrelli G., Ciccone A., Lanari A., Scoditti U., Denti L., Mancuso M., Maccarrone M., Ulivi L., Orlandi G., Giannini N., Gialdini G., Tassinari T., De Lodovici M.L., Bono G., Rueckert C., Baldi A., D'Anna S., Toni D., Letteri F., Giuntini M., Lotti E.M., Flomin Y., Pieroni A., Kargiotis O., Karapanayiotides T., Monaco S., Baronello M.M., Csiba L., Szabó L., Chiti A., Giorli E., Del Sette M., Imberti D., Zabzuni D., Doronin B., Volodina V., Michel P., Vanacker P., Barlinn K., Pallesen L.-P., Barlinn J., Deleu D., Melikyan G., Ibrahim F., Akhtar N., Gourbali V., Caso V.en
dc.date.accessioned2023-01-31T09:41:17Z
dc.date.available2023-01-31T09:41:17Z
dc.date.issued2018
dc.identifier10.1161/JAHA.118.010133
dc.identifier.issn20479980
dc.identifier.urihttp://hdl.handle.net/11615/77421
dc.description.abstractBackground—In patients with acute ischemic stroke and atrial fibrillation, early anticoagulation prevents ischemic recurrence but with the risk of hemorrhagic transformation (HT). The aims of this study were to evaluate in consecutive patients with acute stroke and atrial fibrillation (1) the incidence of early HT, (2) the time to initiation of anticoagulation in patients with HT, (3) the association of HT with ischemic recurrences, and (4) the association of HT with clinical outcome at 90 days. Methods and Results—HT was diagnosed by a second brain computed tomographic scan performed 24 to 72 hours after stroke onset. The incidence of ischemic recurrences as well as mortality or disability (modified Rankin Scale scores >2) were evaluated at 90 days. Ischemic recurrences were the composite of ischemic stroke, transient ischemic attack, or systemic embolism. Among the 2183 patients included in the study, 241 (11.0%) had HT. Patients with and without HT initiated anticoagulant therapy after a mean 23.3 and 11.6 days, respectively, from index stroke. At 90 days, 4.6% (95% confidence interval, 2.3-8.0) of the patients with HT had ischemic recurrences compared with 4.9% (95% confidence interval, 4.0-6.0) of those without HT; 53.1% of patients with HT were deceased or disabled compared with 35.8% of those without HT. On multivariable analysis, HT was associated with mortality or disability (odds ratio, 1.71; 95% confidence interval, 1.24-2.35). Conclusions—In patients with HT, anticoagulation was initiated about 12 days later than patients without HT. This delay was not associated with increased detection of ischemic recurrence. HT was associated with increased mortality or disability. © 2018 The Authors.en
dc.language.isoenen
dc.sourceJournal of the American Heart Associationen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85057096663&doi=10.1161%2fJAHA.118.010133&partnerID=40&md5=cdc935482c0ff07fde8d6eb545089289
dc.subjectanticoagulant agenten
dc.subjectantivitamin Ken
dc.subjectanticoagulant agenten
dc.subjectageden
dc.subjectArticleen
dc.subjectatrial fibrillationen
dc.subjectbrain embolismen
dc.subjectbrain hemorrhageen
dc.subjectbrain ischemiaen
dc.subjectcomputer assisted tomographyen
dc.subjectcontrolled studyen
dc.subjectdisease associationen
dc.subjectdrug efficacyen
dc.subjectearly interventionen
dc.subjectfemaleen
dc.subjecthigh risk patienten
dc.subjecthumanen
dc.subjectincidenceen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmortalityen
dc.subjectoutcome assessmenten
dc.subjectpredictive valueen
dc.subjectpriority journalen
dc.subjectRankin scaleen
dc.subjectrecurrent diseaseen
dc.subjectrisk assessmenten
dc.subjectrisk factoren
dc.subjecttime to treatmenten
dc.subjecttransient ischemic attacken
dc.subjectatrial fibrillationen
dc.subjectbrain hemorrhageen
dc.subjectcerebrovascular accidenten
dc.subjectclinical trialen
dc.subjectcomplicationen
dc.subjectdiagnostic imagingen
dc.subjectmulticenter studyen
dc.subjectneuroimagingen
dc.subjectoral drug administrationen
dc.subjectprospective studyen
dc.subjecttime factoren
dc.subjecttreatment outcomeen
dc.subjectx-ray computed tomographyen
dc.subjectAdministration, Oralen
dc.subjectAgeden
dc.subjectAnticoagulantsen
dc.subjectAtrial Fibrillationen
dc.subjectCerebral Hemorrhageen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectIncidenceen
dc.subjectMaleen
dc.subjectNeuroimagingen
dc.subjectProspective Studiesen
dc.subjectRisk Factorsen
dc.subjectStrokeen
dc.subjectTime Factorsen
dc.subjectTomography, X-Ray Computeden
dc.subjectTreatment Outcomeen
dc.subjectAmerican Heart Association Inc.en
dc.titleHemorrhagic transformation in patients with acute ischemic stroke and atrial fibrillation: Time to initiation of oral anticoagulant therapy and outcomesen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής